Alyeska Investment Group, L.P. Macrogenics Inc Transaction History

Alyeska Investment Group, L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$15.91 - $21.88 $795,500 - $1.09 Million	-50,000 Reduced 33.33%	100,000 $1.61 Million
Q1 2018 May 15, 2018	BUY	$18.89 - $32.46 $2.83 Million - $4.87 Million	150,000 New	150,000 $3.77 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $224M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.